Centene Corporation (NYSE: CNC), a leading healthcare enterprise focused on improving the lives of its members, has provided its financial guidance for 2025 during its investor day event. The company reaffirmed its commitment to delivering high-quality care to more than…
CVS Health Corporation (NYSE: CVS) has announced the results of its previously disclosed cash tender offer (the “Any and All Tender Offer”) for its 4.100% Senior Notes due 2025 (the “Any and All Notes”). As of 5:00 p.m. New York…
BrightPath Bio (Tokyo Stock Exchange Growth 4594), a leader in iPS cell-derived Natural Killer T (NKT) cell therapy, and Cellistic, a pioneer in advanced iPS cell therapy manufacturing, have announced a new agreement focused on process development and manufacturing. The…
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the conditional approval of WELIREG® (belzutifan). This oral…
Newron Pharmaceuticals S.p.A. has entered into a license agreement with EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd., to develop, manufacture, and commercialize Newron’s innovative glutamate modulator, evenamide, for the treatment of schizophrenia in Japan and other Asian…
Gilead Sciences, Inc. (Nasdaq: GILD) recently announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for the approval of seladelpar in treating primary biliary cholangitis (PBC). This treatment, which can…
Geron Corporation (Nasdaq: GERN), a biopharmaceutical company focused on blood cancer treatments, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of RYTELO™ (imetelstat)…
Galderma has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the marketing authorization of nemolizumab for the treatment of both atopic dermatitis and prurigo nodularis in the European…
Klick Health has announced the Grand Prize winner of the $1,000,000 Klick Prize, following the submission of several hundred AI ideas from employees for life sciences clients. The company shared key insights from its year-long internal contest and discussed the…
Nintx (Next Innovative Therapeutics), a Brazilian biotech company focused on developing treatments for multifactorial diseases using Brazil’s rich biodiversity, has raised an additional US$ 10 million following a US$ 3 million seed investment in 2022. This new funding will support…